Executive Order 14370: Increasing Medical Marijuana and Cannabidiol Research

This executive order addresses longstanding gaps in federal research on medical marijuana and cannabidiol (CBD), citing widespread use alongside limited clinical guidance. It highlights the need to modernize research infrastructure, reassess marijuana’s federal classification, and improve oversight of hemp-derived cannabinoid products. By prioritizing real-world evidence and patient safety, the order aims to better inform healthcare providers, regulators, and policymakers navigating a rapidly evolving medical and regulatory landscape.